Skip to content

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on inflammation levels and neurocognition in elderly patients with covid -19

Effects of Transcutaneous Auricular Vagus Nerve Stimulation on inflammation levels and neurocognition in elderly patients with covid -19

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068035
Enrollment
Unknown
Registered
2023-02-03
Start date
2023-01-28
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

trial:taVNS
sham stimualtion:taVNS

Sponsors

Shanghai Yangzhi Rehabilitation Hospital(Shanghai sunshine Rehabilitation Center)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. >= 65 years old; 2. COVID-19 with cough and respiratory involvementand the course of the disease is less than 2 months; 3. Oxygen saturation >93% without the need for mechanical ventilation or severe respiratory insufficiency that will require immediate intubation; 4. The patient has some cognitive ability and can do a simple cognitive assessment; 5. This study was approved by a medical ethics committee with the informed consent of patients or their families.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cognitive impairment; 2. Already enrolled in a clinical trial for COVID-19; 3. History of aneurysm, intracranial hemorrhage, brain tumor, or significant head trauma; 4. Known or suspected severe atherosclerotic cardiovascular disease,severe carotid artery disease, congestive heart failure, known severe coronary artery disease, or recent myocardial infarction; 5. Uncontrolled high blood pressure; 6. Presence of an implanted electrical and/or neurostimulator device, metal cervical spine material, or a metal implant near the site of nVNS; 7. Currently taking medication to improve her cognitive function.

Design outcomes

Primary

MeasureTime frame
IL-6;C-reactive protein, CRP;

Secondary

MeasureTime frame
Mini-Mental State Examination, MMSE;Heart rate variablity, HRV;Self-Rating Depression Scale, SDS;S100ß;

Countries

China

Contacts

Public ContactBin Yu

Shanghai Yangzhi Rehabilitation Hospital(Shanghai sunshine Rehabilitation Center)

yubin@tongji.edu.cn+86 139 1810 8880

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026